Literature DB >> 24179312

Ultra-trace analysis of 41Ca in urine by accelerator mass spectrometry: an inter-laboratory comparison.

George S Jackson1, Darren J Hillegonds, Paul Muzikar, Brent Goehring.   

Abstract

A 41Ca interlaboratory comparison between Lawrence Livermore National Laboratory (LLNL) and the Purdue Rare Isotope Laboratory (PRIME Lab) has been completed. Analysis of the ratios assayed by accelerator mass spectrometry (AMS) shows that there is no statistically significant difference in the ratios. Further, Bayesian analysis shows that the uncertainties reported by both facilities are correct with the possibility of a slight under-estimation by one laboratory. Finally, the chemistry procedures used by the two facilities to produce CaF2 for the cesium sputter ion source are robust and don't yield any significant differences in the final result.

Entities:  

Keywords:  41Ca; Bayesian statistics; accelerator mass spectrometry; interlaboratory comparison

Year:  2013        PMID: 24179312      PMCID: PMC3810309          DOI: 10.1016/j.nimb.2013.08.004

Source DB:  PubMed          Journal:  Nucl Instrum Methods Phys Res B        ISSN: 0168-583X            Impact factor:   1.377


  8 in total

1.  41Ca ultratrace determination with isotopic selectivity > 10(12) by diode-laser-based RIMS.

Authors:  P Müller; B A Bushaw; K Blaum; S Diel; C Geppert; A Nähler; N Trautmann; W Nörtershäuser; K Wendt
Journal:  Fresenius J Anal Chem       Date:  2001-07

2.  Development of 41Ca-based pharmacokinetic model for the study of bone remodelling in humans.

Authors:  Manju Sharma; Zeljko Bajzer; Susanta K Hui
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

3.  41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients.

Authors:  Robert L Fitzgerald; Darren J Hillegonds; Douglas W Burton; Terrance L Griffin; Scott Mullaney; John S Vogel; Leonard J Deftos; David A Herold
Journal:  Clin Chem       Date:  2005-09-01       Impact factor: 8.327

4.  Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca.

Authors:  J M K Cheong; B R Martin; G S Jackson; D Elmore; G P McCabe; J R Nolan; S Barnes; M Peacock; C M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2006-12-05       Impact factor: 5.958

5.  Labeling the human skeleton with 41Ca to assess changes in bone calcium metabolism.

Authors:  E Denk; D Hillegonds; J Vogel; A Synal; C Geppert; K Wendt; K Fattinger; C Hennessy; M Berglund; R F Hurrell; T Walczyk
Journal:  Anal Bioanal Chem       Date:  2006-10-11       Impact factor: 4.142

6.  Interpretation of 41Ca data using compartmental modeling in post-menopausal women.

Authors:  Wang-Hee Lee; Meryl E Wastney; George S Jackson; Berdine R Martin; Connie M Weaver
Journal:  Anal Bioanal Chem       Date:  2010-12-09       Impact factor: 4.142

7.  Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.

Authors:  Eberhard Denk; Darren Hillegonds; Richard F Hurrell; John Vogel; Karin Fattinger; Hans J Häuselmann; Marius Kraenzlin; Thomas Walczyk
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

8.  Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.

Authors:  C M Weaver; B R Martin; G S Jackson; G P McCabe; J R Nolan; L D McCabe; S Barnes; S Reinwald; M E Boris; M Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958

  8 in total
  1 in total

1.  A Bayesian approach to an interlaboratory comparison.

Authors:  George S Jackson; Paul Muzikar; Brent Goehring
Journal:  Chemometr Intell Lab Syst       Date:  2014-12-27       Impact factor: 3.491

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.